2024 Keynote & Featured Presentations

WEDNESDAY, JANUARY 17

Plenary Fireside Chat:
Supporting and Driving Biotech: Past, Present and Future

MODERATOR:
Jennifer Giottonini Cayer, CBO Pulmocide; Board of Directors, UCSD Moores Cancer Center and Biocom California

PANELISTS:
Carter A. Mitchell, PhD, CSO, Purification & Expression, Kemp Proteins, LLC

Deborah Moore-Lai, PhD, Senior Director, Protein Development & Production, Abcam

Eric Vajda, PhD, Vice President, Preclinical R&D, OmniAb

THURSDAY, JANUARY 18

Protein and Gene Therapy Biotherapeutics:
Biophysics, Simulations and Analytical Tools to Shed Light on Biomanufacturability and Downstream Bioprocessing Opportunities

Steven M. Cramer, PhD, William Weightman Walker Professor, Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute

Keynote & Featured Speakers by Pipeline

Antibody Discovery & Engineering

Better Medicines, Created Rapidly through de novo Protein Design
Chris Bahl, PhD, CSO and Co-Founder, AI Proteins

Predicting Antibody Developability at the Discovery Stage
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan

Bispecific Antibody Development

Recent Progress in Antibody-Drug Conjugate Therapy for Cancer
Aditya Bardia, MD, Director, Breast Cancer Research, Harvard Medical School

Tailoring Bispecifics and ADCs Drug Development to Patient and Tumor Features for Safety and Efficacy Optimization: The Clinical Perspective
Elisa Fontana, MD, PhD, Oncologist and Medical Director, Sarah Cannon Research Institute UK

Avidity Engineering for Bispecific and Multispecific Antibodies
Paul Parren, PhD, CSO, Gyes; Professor, Molecular Immunology, Leiden University Medical Center

Predicting Antibody Developability at the Discovery Stage
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan

Characterization & Aggregation in Biopharmaceuticals

Frozen State Protein Aggregation and Its Impact on Biologic Process Development
Bharat Jagannathan, PhD, Principal Scientist, Attribute Sciences, Amgen Inc.

The Role of Interactome in Host Cell Protein Composition in Downstream Processing
Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)

Connecting the Lab to the Machine: A Retrospective Analysis and Prospective Evaluation
Michael S. Marlow, PhD, Director Biologics CMC Research, Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.

Vector Design & Delivery

Synthetic Biology and AI—How These Tools Enable a New Frontier When Combined with the Manufacturing and Design Capabilities of RNA
Charles Jones, PhD, Senior Director, mRNA Commercial Strategy & Innovation, Pfizer Inc.

Navigating CMC Regulations for Viral Vectors: A Comprehensive Guide
Mauricio S. Umana, PhD, Executive Director, Regulatory Affairs CMC, Regulatory Affairs CMC, MassBiologics

Higher-throughput Bioproduction

Engineering Out Metabolic Barriers in CHO Cells
Nathan Lewis, PhD, Associate Professor, Pediatrics and Bioengineering, University of California, San Diego (UCSD)

Identifying Drivers of Cellular Productivity Using HRP-Based Proximity Labeling
Frances Maureen Rocamora, PhD, Project Scientist, Pediatrics, University of California, San Diego